FdaApplication
NDA 210496
Identifiers
- fda_app_no: NDA210496
Properties
| Property | Value |
|---|---|
| applicant_name | ARRAY BIOPHARMA INC |
| application_type | NDA |
| approval_date | 2018-06-27 |
Revenue by product
BRAFTOVI
| Period | Revenue |
|---|---|
| Q2 2026 | $223.0M |
| Q1 2026 | $174.0M |
| Q3 2025 | $202.0M |
| Q2 2025 | $182.0M |
| Q1 2025 | $136.0M |
| Q3 2024 | $173.0M |
| Q2 2024 | $148.0M |
| Q1 2024 | $116.0M |
| Q4 2023 | $57.0M |
| Q3 2023 | $187.0M |
| Q2 2023 | $163.0M |
| Q1 2023 | $152.0M |
| Q4 2022 | $38.0M |
| Q3 2022 | $58.0M |
| Q2 2022 | $51.0M |
| Q1 2022 | $48.0M |
| Q4 2021 | $51.0M |
| Q3 2021 | $47.0M |
| Q2 2021 | $42.0M |
| Q1 2021 | $47.0M |
| Q4 2020 | $44.0M |
| Q3 2020 | $42.0M |
| Q2 2020 | $36.0M |
| Q1 2020 | $37.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| BRAFTOVI | ENCORAFENIB | 50MG | CAPSULE;ORAL |
| BRAFTOVI | ENCORAFENIB | 75MG | CAPSULE;ORAL |
2 products